Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
With a standard review, FDA set a PDUFA target action date of May 16, 2024FORT LEE, N.J., July 17, 2023...